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The presence of an oral squamous cell carcinoma (OSCC) may be associated with increased urinary excretion of the markers of
collagen degradation, hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP). We investigated the possibility of these markers
predicting the presence of active disease. Patients from a current study on HP and LP were included as follows: Group 1a (OSCC
with confirmed mandibular bony infiltration, n¼12), group 1b (group 1a patients 46 months after successful treatment), group 2a
(OSCC without evidence of mandibular bone infiltration, n¼8), group 2b (group 2a patients 46 months after successful treatment),
group 3a (recurrent OSCC, n¼8), group 3b (group 3a patients 46 weeks later, symptoms unchanged) and group 4 (control group,
n¼74). Tissue samples from tumour tissue and adjacent healthy mucosa were additionally investigated for HP and LP concentrations
(n¼8). The decrease in the urinary concentrations of HP and LP was statistically significant between groups 1a and 1b (Po0.001 for
HP and LP), but not between groups 2a and 2b (P¼0.07 for HP and LP), while values in groups 1b and 2b were within the normal
range. When comparing groups 3a and 3b, a significant increase was observed for LP (P¼0.050), but not HP (P¼0.208). In
conclusion, successful treatment of OSCC with bony involvement may be associated with a reduction of urinary HP and LP, whereas
ongoing disease may result in an increase of LP. HP and LP may both be useful markers of tumour progression in patients with OSCC.
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Hydroxylysylpyridinoline (HP) and lysylpyridinoline (LP) are two
nonreducible crosslinks of mature collagen, which are formed by a
sequence of post-translational modifications. HP is a derivative of
three residues of hydroxylysine, and is present in virtually all
mature tissues (tendon, vessel wall, cartilage, dentine and bone).
LP is a derivative of two residues of hydroxylysine and one residue
of lysine, and is found primarily in dentine and bone (Body and
Delmas, 1992; Eyre, 1992; Miyamoto et al, 1994; Acil et al, 1996,
2002a,b; Papatheofanis, 1997; Tamada et al, 2001; Jepsen et al,
2003; Springer et al, 2003a,b).
It has been suggested that the detection of LP in the serum or
urine may be a helpful marker in establishing and possibly
quantifying bone matrix resorption (Body and Delmas, 1992;
Miyamoto et al, 1994; Vinholes et al, 1996; Papatheofanis, 1997;
Tamada et al, 2001; Springer et al, 2003a). In a previous study, we
were able to assess the range and upper limit (HPmax and LPmax)o f
normal values. We were able to show that the measurement of LP
in the urine was able to separate a group of patients with oral
squamous cell carcinoma (OSCC) with bone infiltration from
patients with OSCC without bone infiltration with a sensitivity of
100% and a specificity of 100% (Springer et al, 2003a). In that
paper, we suggested that when the level of LP exceeds LPmax in a
patient with a confirmed OSCC, bony invasion by the malignant
process is highly likely and further investigations to confirm this
should be performed. We also suggested that a urinary level of LP
less than LPmax in patients with OSCC obviated the need for such
investigations (Springer et al, 2003a). We found that urinary HP is
not specific for bony invasion, but may nonetheless be increased in
the urine of patients with bony metastases as compared to patients
without bony metastases. The average urinary HP concentration is
also higher in patients with OSCC without mandibular bony
invasion than in controls (Springer et al, 2003a). We were able to
demonstrate that increasing or increased values of HP and LP are
associated with the presence of tumour tissue. The presence of
such tissue could be detected with a sensitivity of 90% and
specificity of 65% whether bone was infiltrated or not (Springer
et al, 2003a). The urinary levels of HP and, in particular, LP have
been shown to be increased in patients with bony metastases from
multiple myeloma, carcinoma of the breast, lung, prostate gland,
kidney, throat and digestive tract (Takeuchi et al, 1996;
Papatheofanis, 1997; Walne et al, 1997; Yoshida et al, 1997;
Coleman et al, 1999; Marttunen et al, 1999; Tamura et al, 1999;
Woitge et al, 1999, 2001; Demers et al, 2000; Fontana and Delmas,
2000; Liubimova et al, 2000; Izumi et al, 2001; Tamada et al, 2001).
Conventional tumour markers are released by neoplastic tissue,
progressively dedifferentiated subclones may not necessarily
express the same specific markers (Mendelsohn, 1995). The aim
of this study was to evaluate the predictive value of a reduction in
HP and LP in patients with OSCC after successful treatment and of
constant or increasing values in patients with ongoing disease. Revised 15 July 2003; accepted 31 July 2003
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increased urinary concentrations of HP and LP in patients with
OSCC. For this purpose, tissue samples were analysed. While
tumour markers, in general, are specific for certain tumours and
are presumed to be released from neoplastic tissue (Mendelsohn,
1995), HP and LP indicate the destruction/resorption of healthy
mature collagen in the surrounding tissue. To the best of our
knowledge, no analysis of the concentrations of HP and LP in
carcinomatous tissue for intraindividual comparison with normal
tissue has been performed to date.
Patients included in our previous study were followed up in
order for us to observe intraindividual variations in urinary HP
and LP excretion. The authors hypothesised that a successful
treatment of patients with OSCC with and without bony infiltration
leads to a reduction of urinary HP and LP concentrations toward
the normal range, and that ongoing disease might be associated
with constant or increasing values. Furthermore, the authors
hypothesised that increased values of urinary HP and LP in
patients with OSCC are due to the resorption of mature collagen in
tissues adjacent to the carcinoma.
MATERIALS AND METHODS
Patients were recruited from the Cancer Clinic in the Department
of Oral and Maxillofacial Surgery, University of Kiel, Germany. We
obtained 56 urinary samples from 28 patients (age range 44–88
years). The controls were those used in our previous paper
(Springer et al, 2003a).
Group 1a (n¼12):
Samples of patients with OSCC (pT4 N1-2 M0) with bone
infiltration (eight females, four males; six patients 49–60 years
of age; six patients 61–88 years of age).
Group 1b (n¼12):
Samples of patients of group 1a at least 6 months after successful
treatment with no sign of recurrence.
Group 2a (n¼8):
Samples of patients with OSCC (pT1-3 N0-1) with no bony
infiltration (one female, seven males, two patients 44–60 years of
age; six patients 61–81 years of age).
Group 2b (n¼8):
Samples of patients of group 2a at least 6 months after successful
treatment with no sign of recurrence.
Group 3a (n¼8):
Samples of patients with disease recurrence where no treatment
was undertaken (four females, four males; five patients 52–60
years of age; three patients 61–83 years of age).
Group 3b (n¼8):
Samples of patients of group 3a more than 6 weeks later,
symptoms unchanged, where no treatment had been performed.
Group 4 (n¼74):
Control patients without disease (53 males, 21 females; 28 patients
36–60 years of age; 56 patients 61–91 years of age) as described
elsewhere (Springer et al, 2003a).
As stated in our previous paper, patients who were seen in our
regular follow-up programme after apparently adequate initial
treatment of OSCC were included as controls, if treatment had
been completed more than a year prior to entry into the study. In
this group, an R0-resection andoT2-disease were required for
inclusion as a control. Patients who had had a history of
malignancy other than OSCC or had documented alterations in
renal function (urea 450mgdl
 1, creatinine 41.2mgdl
 1) were
excluded. Recall patients were excluded if a prior recurrence had
been documented and successfully treated. Patients were also
excluded if they had had a surgical procedure or a trauma less than
6 months prior to entry into the study (see Results). Patients in
groups 1a, 2a and 3a were staged by ultrasound and computed
tomography. Technetium 99m methylene diphosphonate (MDP)
bone scans with planar imaging and single-positron emission
computed tomographies (SPECTs) were additionally performed on
all patients included in the study (with the exception of the
controls). A chest X-ray, abdominal ultrasound, endoscopic
examination of the upper aerodigestive tract and gynaecological
investigations in female patients completed the invesitagions for a
concomitant disease process. The histopathological examination
was performed by a single pathologist. Patients of groups 1b, 2b
and 3b were staged by ultrasound and clinical examination only.
Tissue samples
Tissue samples were taken from tumour tissue and adjacent
healthy mucosa for intraindividual comparison (n¼8). Resection
margins were left undisturbed for histographic control.
Preparation and hydrolysis of urine
Samples were taken in the morning and stored at  701C until
further processing. All laboratory investigations were performed in
a single laboratory. HP and LP levels seem to be stable in urine
samples for over 10 years if samples are stored at this temperature.
The urine samples were centrifuged at 1000r.p.m. for 5min. A
measure of 2ml of supernatant was lyophilised and subsequently
redissolved in 2ml 6 N hydrochloric acid. The samples were
hydrolysed at 1101C for 24h and centrifuged at 1000r.p.m. for
5min. A volume of 1ml of each hydrolysate was added to a
mixture of 1ml glacial acetic acid, 2ml n-butan-1-ol and 5ml 10%
CF-1-slurry (fibrous cellulose powder, Whatman, Maidstone,
England). The CF-1-slurry was composed of 10% (wv
 1) CF-1 in
a mobile phase containing n-butan-1-ol, glacial acetic acid and
water (4:1:1). A column was prepared by adding the mixture of
hydrolyzate and CF-1-slurry as described above to an econo-
column polyprop (40 8mm
2, Bio-Rad Mu ¨nchen, Germany). The
resin was washed three times with 5ml of the mobile phase.
Subsequently, the pyridinium-containing eluate was eluted from
the column with 3 2ml distilled water into a 15ml plastic tube
and traces of n-butan-1-ol were removed from the surface of the
eluate. Thereafter, the lyophilised eluate was redissolved in 1ml
0.22% (vv
 1) n-heptafluorobutyric acid (HFBA) and centrifuged at
1000r.p.m. for 5min. A volume of 200ml of the sample were
analysed by HPLC (as below). The variations within and between
series were 2 and 4.8%, respectively.
Preparation and hydrolysis of biopsies
Preparation and analysis of tissue samples was performed as
described in our previous studies (Acil et al, 2002b; Jepsen et al,
2003). Tissue samples were subsequently dissolved in 1ml 6 M
hydrochloric acid and hydrolysed at 1101C for 24h and centrifuged
at 1000r.p.m. for 5min. A volume of 1ml of each hydrolysate was
added to a mixture of 1ml acetic acid, 2ml n-butan-1-ol and 5ml
10% CF-1-slurry (fibrous cellulose powder, Whatman, Maidstone,
England). Further preparation was performed as described for the
urine samples above.
Pyridinoline standards
The HP and LP were quantified by external standards gained from
a commercially available adult bovine bone gelatin (Deutsche
Gelatine-Fabriken Stoess, Eberbach/Baden, Germany) prior to the
application of the samples to the chromatography system. HP and
LP were purified by a preparative reverse-phase-column HPLC and
the degree of purity was verified by amino-acid analysis (498% of
dry weight) according to a method previously described (Acil and
Mu ¨ller, 1994; Acil et al, 1996, 2000). Serial dilutions of HP between
0 and 2250pmolnmol
 1 and LP 0 and 1200pmolml
 1 were
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standards.
Analysis of HP and LP by reverse-phase-column HPLC
Chromatography was performed on a Dionex HPLC system
(Idstein, Germany) at 221C. The flow rate was 0.7mlmin
 1 using
two continually degassed solvents: (A) 0.22% (vv
 1) HFBA in
water and (B) 0.22% (vv
 1) HFBA in 80% (vv
 1) acetonitrile. The
resin (Inertsil ODS-3 5mm, 125 4.6mm
2 C18) was equilibrated
with 18/82% solvent B to solvent A prior to the application of the
sample (200ml in 0.22% (vv
 1) HFBA in water). The column was
washed with 18/82% (vv
 1; B/A) for 5min and developed with the
following step gradients:
1. Solvent B (18–20%) over 20min; the peaks of HP and LP were
eluted at approximately 18 and 20min.
2. Solvent B (20–25%) in 4min.
3. Solvent B (25–100%) in 1min plus washing of the column for
another 5min with 100% solvent B.
4. In all, 100–18% over solvent B in 4min, and 1min was used for
column equilibration, thereafter. The next sample was injected
after 35min.
Fluorescence measurements were obtained with an excitation
wavelength of 297nm and emission wavelength of 397nm and the
concentrations of HP and LP expressed in pmolml
 1. After
dilution (1:20) of 1ml of patient urine, the urinary creatinine
content was measured by the colorimetric Jaffe ´-reaction and
expressed in mgdl
 1 (Beckman Creatinine Analyzer 2, USA). The
urinary content of HP and LP was expressed in relation to the
urinary creatinine concentration, that is, in nmolmmol
 1 creati-
nine.
Statistical analysis
There was no statistically significant difference between the sexes,
and a normal distribution of the urinary concentrations of HP and
LP was seen in the different experimental groups. The arithmetic
mean of the urinary levels of HP and LP of the control group
(group 4) was calculated and 1.96 s.d. used to define the normal
range. These upper limits were called HPmax and LPmax (Springer
et al, 2003a). A Wilcoxon matched pair signed-rank test was
performed to evaluate the statistical significance of differences
between groups 1a and b, 2a and b as well as 3a and b. To evaluate
the statistical significance of the difference of the concentration of
HP and LP in tissue samples taken from healthy mucosa and
carcinoma tissue, the Wilcoxon matched pair signed-rank test was
performed. Finally, the average urinary concentrations of HP and
LP of groups 1a, 2a, 3a, 1b, 2b and 3b were compared with the
control group and a two-tailed Mann–Whitney U-test was used to
determine the significance of differences between these groups
(level of significance Po0.05).
Ethics
The study was conducted in accordance with the standards of the
Ethics Committee of the University of Kiel (chairman: Ju ¨rgen
Schaub, MD, PhD, Professor for Pediatrics, Head of the Depart-
ment of Pediatrics, University of Kiel, Germany; registration
number of the present study: AZ D 309/01) and with the Helsinki
Declaration of 1983. The patients were informed about the aim and
design of the study and written consent was obtained.
RESULTS
The decrease in urinary HP and LP concentrations was statistically
significant between groups 1a and 1b (Po0.001 for HP and LP,
Figure 1), but not between groups 2a and 2b (P¼0.07 for HP and
LP). As compared to group 4 (controls), the urinary concentra-
tions of all patients in group 2b were within the normal range while
two values for both LP and HP in group 1b were higher than HPmax
and LPmax (Figure 2). Urinary concentrations of HP of groups 1a
and 1b overlapped in five out of 12 patients, while urinary
concentrations of bone-specific LP overlapped in only two out of
12 patients. When comparing the urinary concentrations of group
3a with group 3b, a further significant increase was observed for
LP (P¼0.050), but not HP (P¼0.208) with both HP and LP being
increased further in two out of eight patients. No statistically
significant difference was found between groups 1b (follow-up of
patients with OSCC with bony infiltration after apparently
successful treatment) and 4 (controls, P¼0.195 for HP and
P¼0.107 for LP) as well as groups 2b (follow-up of patients with
treated for OSCC without bony infiltration) and 4 (con-
trol,P¼0.077 for HP and P¼0.68 for LP). The differences between
groups 3a (recurrence group) and 4 (controls, Po0.001 for HP and
Po0.001 for LP) as well as 3b (follow-up of patients with
recurrence) and 4 (control, Po0.001 for HP and Po0.001 for
LP) were statistically significant. The average urinary concentra-
tion of HP (Po0.05) but not LP (P¼0.20) was significantly
increased in group 2a as compared to group 4. The average urinary
levels of HP and LP in nmolmmol
 1 creatinine are shown in
Figure 2. Details are provided in Table 1.
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Figure 1 Chromatograms of a patient of group 1a (OSCC with
mandibular bony infiltration) at the time of diagnosis (A) and group 1b (6
months after successful treatment) (B). The fluorescence was monitored
with excitation at 297nm and emission at 397nm. The HP peak arose at
17.5min after injection, followed by the LP peak. Of note are the
decreased HP and LP peaks in group 1b as compared to group 1a.
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were significantly lower in carcinomatous tissue as compared to
healthy mucosa. In six out of eight tissue samples and in seven out
of eight mucosa samples, minor concentrations of LP were found
(Figure 3, Table 2).
DISCUSSION
We set out to assess the ability of a decrease of urinary HP and LP
concentrations in patients with OSCC after successful treatment,
and the value of constant or increasing values in patients with
ongoing disease. We were able to show that the decrease in urinary
HP and LP concentrations was statistically significant between
patients with OSCC with bony infiltration and 6 months after
successful treatment for this disease (Po0.001 for HP and LP). The
authors of the present study would like to point out that urinary
concentrations of HP of groups 1a and 1b overlapped in five out of
12 patients, while urinary concentrations of bone-specific LP
overlapped in only two out of 12 patients. The reduction of urinary
concentrations of LP after successful treatment appears to be of
greater significance when compared to the reduction of urinary
concentrations of HP. However, a Wilcoxon matched pair signed-
rank test was employed to test for significant differences of urinary
concentrations of the patients in the course of an intraindividual
follow-up. The significance of intraindividual differences of a
group of patients is addressed by this test, implying that an overlap
of the range of urinary concentrations of HP and LP between
Table 1 Urinary concentrations (nmolmmol
 1 creatinine)
n Mean s.d. Min Max 25th p Median 75th p
HP Group 1a 12 136.70 52.86 56.00 212.50 90.18 145.50 181.05
Group 1b 12 64.62 34.08 13.80 128.20 39.98 58.90 85.25
Group 2a 8 76.81 41.58 23.10 141.30 37.75 75.05 106.50
Group 2b 8 37.59 18.65 16.60 70.83 21.03 32.05 51.38
Group 3a 8 117.02 58.35 49.21 222.50 69.63 97.06 161.62
Group 3b 8 134.26 47.66 71.06 193.94 98.82 118.94 186.30
Group 4 74 50.34 20.47 13.20 94.10 36.02 48.85 66.00
LP Group 1a 12 30.86 7.30 21.02 40.43 23.50 31.92 38.02
Group 1b 12 12.84 6.49 4.72 22.80 8.00 9.82 18.90
Group 2a 8 11.93 5.61 5.50 19.73 5.90 12.67 17.56
Group 2b 8 8.53 3.85 2.97 13.83 5.48 8.02 12.22
Group 3a 8 23.95 5.60 14.37 34.13 21.30 23.84 26.41
Group 3b 8 31.42 7.65 23.27 48.43 26.91 29.36 33.43
Group 4 74 9.32 4.43 1.80 19.10 5.67 8.85 12.58
Group 1a¼OSCC with mandibular bony infiltration; group 1b¼patients in group 1a 46 months after successful treatment; group 2a¼OSCC without mandibular bony
infiltration; group 2b¼patients in group 2a 46 month after successful treatment; group 3a¼untreatable recurrence of OSCC; group 3b¼patients in group 3a at least 6 weeks
later, symptoms unchanged and group 4¼control group, patients without disease n¼74. s.d.¼standard deviation, min¼minimum, max¼maximum, p¼percentile.
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Figure 2 Boxplot, urinary concentrations of HP and LP: each box shows
the median, quartiles and extreme values. Group 1a (OSCC with
mandibular bony infiltration, n¼12), group 1b (samples of patients of
group 1a 46 months after successful treatment), group 2a (OSCC without
mandibular bone infiltration, n¼8), group 2b (samples of patients of group
2a 46 months after successful treatment), group 3a (recurrence of OSCC,
n¼8), group 3b (samples of patients of group 3a 46 weeks later,
symptoms unchanged) and group 4 (control group, patients without
disease n¼74). Lines mark HPmax (95nmolmmol
 1 creatinine) and LPmax
(20nmolmmol
 1 creatinine). In regard to groups 1a and 2a, the LPmax line
separates the LP values completely. (J) Values of patients that significantly
exceeded the normal range in the recurrence group. While values in
groups 1b and 2b approach the normal range as given by group 4 values
exceeded it in groups 3a and 3b.
80
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*
Figure 3 Boxplot of concentrations of HP and LP in carcinoma tissue
(n¼8) and normal mucosa (n¼8) (pmolg
 1): A sample of normal
appearing mucosa as well as a sample of tumour tissue was obtained in
eight patients. Each box shows the median, quartiles and extreme values.
The concentrations of both HP (P¼0.027) and LP (P¼0.017) were
significantly decreased in carcinomatous tissue. It is remarkable that there is
a minor concentration of LP in some of the samples. J and * indicate
extreme values.
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pair signed-rank test showed intraindividual differences of urinary
concentrations of HP and LP to be highly significant (Po0.001 for
HP and LP).
The differences between patients with OSCC without bony
infiltration and values of these patients 6 months after successful
treatment were present, but not statistically significant (P¼0.07
for HP and LP). After successful treatment, values of all patients
with OSCC without bony infiltration were within the normal range.
Two values for both LP and HP of patients with OSCC with bone
infiltration 6 months after successful treatment were greater than
HPmax and LPmax, but were significantly decreased as compared to
the values at the time of diagnosis. Further increases of LP values
and constant HP values in patients with ongoing disease indicated
the sensitivity of the assay. As we were able to show in our
previous study, increased or increasing values of urinary HP and
LP are closely associated with the presence of tumour tissue. The
presence of such tissue could be detected with a sensitivity of 90%
and specificity of 65% (Springer et al, 2003a). The results of this
study suggested that urinary HP and LP concentrations normalise
in patients after successful treatment and increase in patients with
ongoing disease.
Many markers have been evaluated for OSCC, some of
which were tissue polypeptide antigen (TPA), carcinoembryonic
antigen (CEA), surface antigen, 100 Da (S-100), carbohydrate
antigen 19-9 (CA 19-9), CA 125, CA 15-3, squamous cell carcinoma
antigen (SCCA), immunosuppressive acidic protein (IAP),
alpha-foetoprotein (AFP) and ferritin (FER) (Zoller et al, 1990;
Kurokawa et al, 1993; Kuo et al, 1999; Hofele et al, 2002). TPA,
CEA, CA 19-9 and CA125 levels were analysed in a group of
patients with laryngeal or oral cancer pre- and post-therapy (Kuo
et al, 1999). Only TPA and CEA levels decreased significantly after
therapy but clinical use in the disease was described to be limited
(Kuo et al, 1999). Another study analysed serum levels of CEA,
SCCA, IAP, AFP, FER and CA 19-9 in patients with primary OSCC
(Kurokawa et al, 1993). The positive rates were reported to be
34.5% for CEA, 41.4% for SCCA, 51.7% for IAP, 0% for AFP, 10.3%
for FER and 6.9% for CA 19-9, and it was concluded that only a
combination of the analysis of CEA, SCCA and IAP could be of
some value in the diagnosis of OSCC (Kurokawa et al, 1993).
Another study did show that the diagnostic value of the tumour
markers CEA, Ca 19-9, Ca 125, Ca15-3 exhibited a poor sensitivity
in the follow-up of squamous cell carcinoma of the head and neck
(Zoller et al, 1990).
The detection of epithelial tumour RNA in plasma from colon
cancer patients is associated with advanced stages and circulating
tumour cells (Silva et al, 2002). Two different studies regarding
patients with head and neck squamous cell carcinoma (HNSCC)
and OSCC, respectively, found that serum p53 antibody is a
significant prognostic factor for nodal metastasis (Chow et al,
2001; Hofele et al, 2002).
CYFRA 21-1 but not CYFRA 8/18 serum levels were suggested
to be significantly higher in patients with squamous cell
carcinoma of the head and neck as compared to a control group
and cutoff values were determined (Niemann et al, 1997; Maass
et al, 1999).
Serum vascular endothelial growth factor (s-VEGF) levels were
shown to be significantly increased in patients with advanced
laryngeal carcinoma as compared to healthy controls (Teknos et al,
2002). There were certain indications that elevated pretreatment s-
VEGF levels might indicate a more aggressive disease state and a
poorer overall survival in laryngeal carcinoma (Teknos et al, 2002).
Also, it could be shown that OSCC is associated with significantly
increased s-VEGF concentrations and it was suggested that the
measurement of the s-VEGF concentration may be helpful to
distinguish OSCC patients from healthy individuals (Shang et al,
2002).
In contrast to HP and LP, conventional markers such as those
named above are in general specific for a certain tumour disease
and are thought to be released by neoplastic tissue (Mendelsohn,
1995). Dedifferentiated subclones of the tumour may not
necessarily express the same specific marker (Mendelsohn,
1995). Carcinomas are epithelial in origin (Reichart and Philipsen,
1999) and therefore the direct release of HP and LP, which are
crosslink residues of mature collagen, is highly unlikely.
To the best of our knowledge, the analysis of the concentration
of HP and LP in carcinomatous tissue for intraindividual
comparison with normal tissue has not been performed in any
kind of neoplasm. We were able to show that the concentrations of
HP and LP is significantly decreased in carcinoma tissue as
compared to mucosa (P¼0.027 for HP and P¼0.017 for LP). We
suggest that the destruction of healthy mature collagen in the
course of tissue invasion by OSCC tissue is responsible for the
release of increased amounts of HP and LP and that therefore
urinary HP and LP are progression/invasion markers of OSCC. An
advantage in using HP and LP in the follow-up of patients with
OSCC is that the sensitivity of these markers is independent of the
state of differentiation of the carcinoma.
Minor concentrations of LP in both tumour tissue and
healthy tissue indicate that it is not completely specific for dentin
and bone as indicated earlier (Body and Delmas, 1992; Miyamoto
et al, 1994; Vinholes et al, 1996; Papatheofanis, 1997; Tamada et al,
2001; Acil et al, 2002b; Springer et al, 2003a,b). The measurement
of LP in the urine has been shown to be 100% sensitive and 100%
specific in indicating whether bone is invaded by an OSCC or not
(Springer et al, 2003a). We suggest that low concentrations of LP in
healthy mucosa and carcinoma tissue have no impact on the
clinical application of the assay in staging and the follow-up of
OSCC.
The cost of detection of urinary HP and LP is low when
performed in a clinical laboratory on a routine basis (Springer et al,
2003a). We suggest that HP and LP could serve as markers of
tumour progression, as urinary levels return to normal after
successful treatment and increase or remain elevated in patients
with a confirmed tumour recurrence. The analysis of the total
urinary HP and LP by the HPLC method as applied in the present
study could be helpful for intraindividual follow-up of patients
with OSCC. We suggest that an intraindividual increase of HP and
Table 2 Concentrations of HP and LP in carcinomatous tissue (n¼8) and normal mucosa (n¼8) (pmolg
 1)
n Mean s.d. Min Max 25th p Median 75th p
HP Normal mucosa 8 25.46 18.51 2.57 66.11 14.50 23.23 27.96
Carcinoma 8 6.98 5.27 0.62 17.82 2.85 6.87 9.12
LP Normal mucosa 8 6.34 5.00 0.00 14.79 2.13 5.58 10.58
Carcinoma 8 1.26 1.48 0.00 3.62 0.08 0.63 2.95
A sample of normal appearing mucosa and a sample of tumour tissue was obtained in eight patients. The concentrations of both HP (P¼0.027) and LP (P¼0.017) were
significantly reduced in carcinoma tissue. It is remarkable that there is a minor concentration of LP in some of the samples.
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clinician to the possibility of a recurrence. As we have shown in
our previous study, urinary HP and LP concentrations are
nonspecific in patients with a previous diagnosis of OSCC. After
a patient has been treated for an OSCC, recurrence can be detected
with a sensitivity of 90%. While false negatives were not observed,
false positives (ca. 18%) have no harmful consequence (Springer
et al, 2003a). In addition to the clinical examination and
ultrasonography, the urinary assay of HP and LP may be valuable
in indicating the presence of recurrence in the course of
intraindividual follow-up.
ACKNOWLEDGEMENTS
We express our gratitude to J Hedderich, BSC (Med. Inf.) for
assistance in statistical analysis.
We gratefully acknowledge our laboratory technicians Messrs
Gisela Otto and Mojgan Paymard for their assistance with the
analytical procedures.
The Department of Oral and Maxillofacial Surgery, University of
Kiel, Germany, financed this project. We express our gratitude
towards to Professor F Ha ¨rle, PhD, Head of the Department, for his
support.
REFERENCES
Acil Y, Brinckmann J, Notbohm H, Muller PK, Batge B (1996) Changes
with age in the urinary excretion of hydroxylysylpyridinoline (HP)
and lysylpyridinoline (LP). Scand J Clin Lab Invest 56:
275–283
Acil Y, Mu ¨ller PK (1994) A rapid method for the isolation of the mature
collagen cross-links, hydroxylysylpyridinoline (HP) and lysylpyridino-
line (LP). J Chromatogr A 664: 183–188
Acil Y, Springer ING, Broek V, Terheyden H, Jepsen S (2002a) Effects of
bone morphogenetic protein-7 stimulation on osteoblasts cultured on
different biomaterials. J Cell Biochem 86: 90–98
Acil Y, Springer ING, Prasse JG, Hedderich J, Jepsen S (2002b)
Concentration of collagen cross-links in human dentin bears no relation
to the individual age. Int J Legal Med 116: 340–343
Acil Y, Terheyden H, Dunsche A, Fleiner B, Jepsen S (2000) Three-
dimensional cultivation of human osteoblast-like cells on highly porous
natural bone mineral. J Biomed Mater Res 51: 703–710
Body JJ, Delmas PD (1992) Urinary pyridinium cross-links as markers of
bone resorption in tumor-associated hypercalcemia. J Clin Endocrinol
Metab 74: 471–475
Chow V, Yuen AP, Lam KY, Ho WK, Wei WI (2001) Prognostic significance
of serum p53 protein and p53 antibody in patients with surgical
treatment for head and neck squamous cell carcinoma. Head Neck 23:
286–291
Coleman RE, Purohit OP, Black C, Vinholes JJ, Schlosser K, Huss H, Quinn
KJ, Kanis J (1999) Double-blind, randomised, placebo-controlled, dose-
finding study of oral ibandronate in patients with metastatic bone
disease. Ann Oncol 10: 311–316
Demers LM, Costa L, Lipton A (2000) Biochemical markers and skeletal
metastases. Cancer 88: 2919–2926
Eyre D (1992) New biomarkers of bone resorption. J Clin Endocrinol Metab
74: 470A–470C
Fontana A, Delmas PD (2000) Markers of bone turnover in bone
metastases. Cancer 88: 2952–2960
Hofele C, Schwager-Schmitt M, Volkmann M (2002) Prognostic value of
antibodies against p53 in patients with oral squamous cell carcinoma –
five years survival rate. Laryngorhinootologie 81: 342–345
Izumi M, Nakanishi Y, Takayama K, Kimotsuki K, Inoue K, Wataya H,
Minami T, Hara N (2001) Diagnostic value of bone-turnover metabolites
in the diagnosis of bone metastases in patients with lung carcinoma.
Cancer 91: 1487–1493
Jepsen S, Springer ING, Buschmann A, Hedderich J, Acil Y (2003)
Elevated levels of collagen cross-link residues in gingival tissues
and crevicular fluid of teeth with periodontal disease. Eur J Oral Sci
111: 198–202
Kuo WR, Lee KW, Ho KY, Tsai SM, Chiang FY, Juan KH (1999) Tissue
polypeptide antigen, carcinoembryonic antigen, carbohydrate antigen,
and CA125 levels as tumor markers in squamous cell carcinoma of the
head and neck. Kaohsiung J Med Sci 15: 152–158
Kurokawa H, Tsuru S, Okada M, Nakamura T, Kajiyama M (1993)
Evaluation of tumor markers in patients with squamous cell carcinoma
in the oral cavity. Int J Oral Maxillofac Surg 22: 35–38
Liubimova NV, Bronnikov II Robins SP, Trapeznikova MF, Kushlinskii NE
(2000) The biochemical markers of bone remodeling in cancer patients
with skeletal involvement. Vopr Onkol 46: 290–297
Maass JD, Niemann AM, Lippert BM, Gottschlich S, Folz BJ, Werner JA
(1999) CYFRA 8/18 in head and neck cancer. Anticancer Res 19: 2699–
2701
Marttunen MB, Hietanen P, Titinen A, Roth HJ, Viinikka L, Ylikorkala O
(1999) Effects of tamoxifen and toremifene on urinary excretion of
pyridinoline and deoxypyridinoline and bone density in postmenopausal
patients with breast cancer. Calcif Tissue Int 65: 365–368
Mendelsohn J (1995) Prinzipien der Neoplasie. In Harrisons Principles of
Medicine, Schmailzl KJ (ed), Vol. 2, pp 245–246. Berlin: Blackwell
Wissenschafts-Verlag
Miyamoto KK, McSherry SA, Robins SP, Besterman JM, Mohler JL (1994)
Collagen cross-link metabolites in urine as markers of bone metastases
in prostatic carcinoma. J Urol 151: 909–913
Niemann AM, Goeroegh T, Gottschlich S, Lippert BM, Werner JA (1997)
Cut-off value determination of CYFRA 21-1 for squamous cell
carcinomas of the head and neck (SCCHN). Anticancer Res 17: 2859–
2860
Papatheofanis FJ (1997) Quantitation of biochemical markers of bone
resorption following strontium-89-chloride therapy for metastatic
prostatic carcinoma. J Nucl Med 38: 1175–1179
Reichart PA, Philipsen HP (1999) Maligne Tumoren. In Oralpathologie,
Rateitschak KH, Wolf HF (eds) pp 108–118. Farbatlanten der
Zahnmedizin. Thieme: Stuttgart
Shang ZJ, Li JR, Li ZB (2002) Circulating levels of vascular endothelial
growth factor in patients with oral squamous cell carcinoma. Int J Oral
Maxillofac Surg 31: 495–498
Silva JM, Rodriguez R, Garcia JM, Munoz C, Silva J, Dominguez G,
Provencio M, Espana P, Bonilla F (2002) Detection of epithelial tumour
RNA in the plasma of colon cancer patients is associated with advanced
stages and circulating tumour cells. Gut 50: 530–534
Springer ING, Terheyden H, Dunsche A, Czech N, Tiemann M, Hedderich J,
Ac¸il Y (2003a) Collagen crosslink excretion and staging of oral cancer. Br
J Cancer 88: 1105–1110
Springer ING, Terheyden H, Gei S, Ha ¨rle F, Ac¸il Y (2003b) Particulated
bone-grafts – effectiveness of bone cell supply. Clin Oral Impl Res, (in
press)
Takeuchi S, Arai K, Saitoh H, Yoshida K, Miura M (1996) Urinary
pyridinoline and deoxypyridinoline as potential markers of bone
metastasis in patients with prostate cancer. J Urol 156: 1691–1695
Tamada T, Sone T, Tomomitsu T, Jo Y, Tanaka H, Fukunaga M (2001)
Biochemical markers for the detection of bone metastasis in patients
with prostate cancer: diagnostic efficacy and the effect of hormonal
therapy. J Bone Miner Metab 19: 45–51
Tamura H, Ishii S, Ikeda T, Enomoto K, Kitajima M (1999) The
Relationship between urinary pyridinoline, deoxypyridinoline and bone
metastasis in a rat Breast Cancer Model. Breast Cancer 6: 23–28
Teknos TN, Cox C, Yoo S, Chepeha DB, Wolf GT, Bradford CR, Carey TE,
Fisher SG (2002) Elevated serum vascular endothelial growth factor and
decreased survival in advanced laryngeal carcinoma. Head Neck 24:
1004–1011
Vinholes J, Guo CY, Purohit OP, Eastell R, Coleman RE (1996) Metabolic
effects of pamidronate in patients with metastatic bone disease. Br J
Cancer 73: 1089–1095
Walne AJ, Jenkins PJ, James IT, Plowman PN (1997) Pyridinium crosslinks
in the monitoring of patients with bone metastases from carcinoma of
the breast. Clin Oncol 9: 30–34
Woitge HW, Pecherstorfer M, Horn E, Keck AV, Diel IJ, Bayer P, Ludwig H,
Ziegler R, Seibel MJ (2001) Serum bone sialoprotein as a marker of
tumour burden and neoplastic bone involvement and as a prognostic
factor in multiple myeloma. Br J Cancer 84: 344–351
Markers of tissue resorption in OSCC
ING Springer et al
1727
British Journal of Cancer (2003) 89(9), 1722–1728 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
yWoitge HW, Pecherstorfer M, Li Y, Keck AV, Horn E, Ziegler R, Seibel MJ
(1999) Novel serum markers of bone resorption: clinical assessment and
comparison with established urinary indices. J Bone Miner Res 14:
792–801
Yoshida K, Sumi S, Arai K, Koga F, Umeda H, Hosoya Y, Honda M, Yano
M, Moriguchi H, Kitahara S (1997) Serum concentration of type I
collagen metabolites as a quantitative marker of bone metastases in
patients with prostate carcinoma. Cancer 80: 1760–1767
Zoller J, Fiehn W, Mende U, Hotz G (1990) The diagnostic value of the
tumor markers CEA, ‘Ca 19-9’, ‘Ca 125’, ‘Ca15-3’ and ‘SCC’ for the
detection of recurrent tumors in patients with tumors of the head and
neck. Dtsch Z Mund Kiefer Gesichtschir 14: 254–259
Markers of tissue resorption in OSCC
ING Springer et al
1728
British Journal of Cancer (2003) 89(9), 1722–1728 & 2003 Cancer Research UK
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y